Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
C4 Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC&#59; U.S. IND Cleared"
05/04/2023 8-K Quarterly results
Docs: "C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDAC™ Degrader&#59; Phase 1/2 Clinical Trial Enrolling Patients"
11/03/2022 8-K Quarterly results
Docs: "C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights"
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 12, 2020 C4 THERAPEUTICS, INC. Delaware 001-39567 47-5617627 490 Arsenal Way, Suite 200 Watertown, MA 02472 Registrant's Telephone Number, Including Area Code: 231-0700 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-...",
"C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy